Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

PROSTATE CANCER

UT-34: a promising new AR degrader

Nature Reviews Urology volume 16, page 640 (2019)Cite this article

Subjects

Access through your institution
Buy or subscribe

UT-34, a newly discovered second-generation selective agent for the degradation of androgen receptor (SARD), degrades enzalutamide-sensitive and enzalutamide-resistant androgen receptors (ARs) and AR splice variants (ARVs) in preclinical models of prostate cancer. This orally bioavailable SARD has promising drug-like characteristics and should progress to clinical development.

UT-34 was selected for further characterization from a library owing to its favourable degradation and antagonistic characteristics and pharmacokinetic properties compared with first-generation SARDs, whose pharmacokinetic properties were inappropriate for further development.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Urology http://www.nature.com/nrurol/

    Louise Stone

Authors
  1. Louise Stone
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Louise Stone.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stone, L. UT-34: a promising new AR degrader. Nat Rev Urol 16, 640 (2019). https://doi.org/10.1038/s41585-019-0248-5

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41585-019-0248-5

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer